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obtained the similar results. CONCLUSIONS: The WTP for QALY in Russia is 63,000
rubles or $2,300 that is much lower than in other countries but WTP/AAI ratio is
nearly the same as in the UK.There are WTP5selWTPselWTPfamWTPsocin
Russia just like in Australia, the UK and the US.
PRM45
IMPORTANCE OF COLLABORATION WITH DEVELOPERS IN THE CLARIFICATION
OF CONCEPTS: A CASE STUDY WITH THE UNIVERSITY OF CALIFORNIA, SAN
DIEGO (UCSD) SHORTNESS OF BREATH QUESTIONNAIRE (SOBQ)
Ries AL1, Kaschinski D2, Montigny C3
1University of California, San Diego, CA, USA, 2Boehringer Ingelheim GmbH, Ingelheim am
Rhein, Germany, 3MAPI Institute, Lyon, France
OBJECTIVES: The UCSD SOBQ, a 24-item instrument developed in US English, as-
sesses self-reported shortness of breath while performing a variety of daily living
activities. The objective of this report is to underline the importance of collabora-
tion with the developers to clarify concepts and ensure their correct interpretation
while translating the original version into other languages. METHODS: Interactive
discussion with the developers of the SOBQ was undertaken to formalize a concept
list that would: 1) Explain and clarify the conceptual notions underlying each item
in simple language so they would be accurately reflected in each language version
produced, and 2) Provide acceptable approved translation alternatives. RESULTS:
The concept list was revised five times and widely expanded with definitions and
alternate translations validated by the developers. Through questions raised dur-
ing the linguistic validation process, collaboration with the developers highlighted
items initially considered as unambiguous but which required additional informa-
tion to be faithfully rendered in all languages. Among the 24 items of the SOBQ, four
items proved to be unclear (e.g., “dressing” was clarified as “putting on and taking
off clothes” and “picking up and straightening” as “picking things up and tidying
them up”). Three other items appeared as culturally inappropriate and, therefore,
needed to be adapted to be suitable to the countries for which these activities were
not relevant (e.g., “washing car or any other vehicle” was one of the accepted
alternatives for “washing car” and “watering flowers” for “watering the lawn”).
CONCLUSIONS: It is essential to involve the developers in the clarification of the
concepts underlying each item in a questionnaire to allow their correct interpre-
tation in other languages and cultures. This step is crucial to ensure comparable
content validity between different language versions. This example with the SOBQ
shows that the involvement of developers is a dynamic and necessary process.
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OBJECTIVES: As the use of clinical outcomes assessments in global studies contin-
ues to rise, and electronic modes of administration proliferate, collaboration be-
tween ePRO and linguistic validation providers becomes critical to the success of
global initiatives. This cooperation enables the incorporation of the electronic
mode of administration into the cognitive interviewing stage of linguistic valida-
tion, allowing respondents to view the content in context. Collaboration between
ePRO and linguistic validation providers also yields time and cost efficiencies to the
sponsor. METHODS: A review of prior collaboration with four ePRO providers was
conducted to provide insight into key areas for efficiency prior to initiation of a
large-scale linguistic validation project involving ePRO. Prior to project initiation, a
detailed workflow was outlined, a review of relevant ePRO file formats was con-
ducted, and processes and milestones were developed with input from the linguis-
tic validation provider, the ePRO provider, and the sponsor to ensure deadlines
were met. RESULTS: Reviews of prior projects revealed early collaboration was
commonly impeded as the development of the ePRO platform often initiates on
different timelines than linguistic validation process. Common reasons include
differing contracting timelines from the sponsor for each service, and addition of
countries or languages after ePRO contract execution. By building a collaborative
project workflow ahead of project initiation, the ePRO and linguistic validation
partners can identify cost and timeline efficiencies in 1) the source content, 2)
uploading the translated language directly into ePRO platforms, 3) use of ePRO
mode in cognitive interviews, 4) post-localization testing of fonts and characters,
and 5) proofreading of the final screenshots. CONCLUSIONS: Timeline restrictions
resulting from study deadlines and contracting processes can limit the benefit to be
achieved by collaboration between ePRO and linguistic validation partners. Early
planning, and contracting of each provider with the expectation of collaboration
will enable cost and timeline efficiencies, and process improvements.
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OBJECTIVES: Since the publication of the FDA PRO Guidance in 2009, focus has
largely been dedicated to patient-reported outcomes measures. Other commonly
used clinical outcomes assessments including clinician-reported outcomes (Clin-
RO) and observer-reported outcomes (Obs-RO) warrant attention, as the expecta-
tion is that all clinical outcomes assessments will be expected to follow the prop-
erties of the PRO guidelines. It can be inferred that the same expectations for
translation and cultural adaptation of these measures will also apply, and discus-
sion surrounding translation methodologies for these outcomes measures is
necessary. METHODS: A review of past Clin-RO and Obs-RO measure translation
methodologies was conducted. Linguistic feedback resulting from each stage was
reviewed for relevance and impact on language changes. RESULTS: Past transla-
tion methodologies involved concept definition, dual forward translation, recon-
ciliation of forward translations, back translation, resolution of back translation
and forward translation, and clinician or expert review for all clinical outcomes
assessments. An additional stage specific to observer-reported outcomes assess-
ments included cognitive interviewing with the relevant respondent population,
such as caregivers, parents, etc. Clin-RO measures involve review by native-speak-
ing clinicians in the relevant area of interest. Cognitive interviews with clinicians
were not found to be a common practice. CONCLUSIONS: The results of this review
and feedback analysis suggest observer-reported outcomes measures are best
suited to follow the same methodology as PRO measures, with the cognitive inter-
views conducted with the relevant observer population. Clinician-reported out-
comes measures should also follow the same guidelines as PRO measures for trans-
lation, however further research into the methodology for execution of the review
stage is required to assess if clinician reviews, focus groups with clinicians, cogni-
tive interviews with clinicians, or an alternative will yield the best results for this
particular clinical outcomes assessment.
Research On Methods – Statistical Methods
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OBJECTIVES: The allocation of sufficient time for participant recruitment is one of
the fundamental aspects in planning a clinical trial (Carter, 2004): the study of
patient accrual is of great interest not only in clinical trials but also in observational
studies. In this work we developed a time-to-event (i.e. survival) model aimed to
explain the course of patients, according to site and study characteristics.
METHODS: Nineteen observational non-retrospective studies (663 sites and 22,123
patients) managed by Medidata from 2002 to 2009 were included in the analysis.
Time to patient enrolment was calculated as the percentage of time elapsed from
the first-patient-in to the enrolment of the patient out of the study planned dura-
tion. Individuals enrolled after this period were considered as censored. Site and
study characteristics were included in a Cox Proportional Hazard regression model;
Hazard Ratios were estimated. RESULTS: The course of patients was significantly
associated with year of the study (2008 vs. 2008: Hazard Ratio 2.37), number of
planned sites (25 vs. 25: 0.63), study design (cross- sectional vs. longitudinal:
0.33), electronic vs. paper data capture (2.87), start-up and investigator meeting
execution (yes vs. no: 2.27 and 0.45 respectively), single patient fee vs. other (1.78),
top-enroller list communication (yes vs no: 0.71), competitive enrolment (yes vs.
no: 0.47), site initiation visit (yes vs. no: 0.38), protocol amendment with possible
effects on enrolment (yes vs. no: 4.21), type of site (academic private hospital/
university/private out-patient clinic vs community hospital: 0.86) and median
monthly number of phone calls/site (1.15). CONCLUSIONS: In our analysis, the
most interesting factors influencing patient accrual in the setting of observational
studies managed by an Italian CRO appeared to be the number of planned sites,
cross- sectional study design, electronic data capture, start-up and investigator
meeting execution, top-enroller list communication and competitive enrolment.
Further analyses are ongoing as regards a predictive model.
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OBJECTIVES: Clinical studies generally include several endpoints to compare the
effects of alternative interventions. Meta-analyses are usually performed on dif-
ferent endpoints separately. We investigated advantages of bivariate meta-analy-
sis models, accounting for the correlation between endpoints, compared to univar-
iate meta-analyses. METHODS: Alternative meta-analysis approaches were
applied and compared using simulated datasets of logarithms of odds ratios (OR)
for two endpoints. Several datasets of 20 studies were simulated, with different
correlations between endpoints, and with or without missing values. Simulations
were based on a bivariate normal distribution with mean log ORs of -0.5, corre-
sponding to ORs of 0.61, and variances of 0.25 for both endpoints. The models used
were: 1) random-effects univariate models for each endpoint separately; 2) two-
stage approach using univariate model for studies with one endpoint and bivariate
model for studies with two endpoints; and 3) bivariate model with prior imputation
of the variance of second endpoint for studies with one endpoint only, based on the
correlation between variances for the two endpoints. All the models were esti-
mated in a Bayesian framework, using WinBugs. RESULTS: Results of different
models were fairly similar in absence of missing data. In a situation with one
endpoint missing at random for 10 studies, and a correlation of 0.8, the bias around
estimated OR for that endpoint was 0.12, 0.03, and 0.04 with models 1, 2 and 3
respectively, when an informative prior was used for the correlation. The bias was
not reduced with uninformative prior. Variance estimates also differed between
models, and were very large with model 2 for some simulations. CONCLUSIONS:
Bivariate meta-analysis can improve treatment effect estimates when information
is collected for two correlated endpoints, especially for an endpoint which is not
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